Maplight Therapeutics
Clinical trials sponsored by Maplight Therapeutics, explained in plain language.
-
Autism drug safety study opens for 120 participants
Disease control ENROLLING_BY_INVITATIONThis study continues testing the safety of an investigational medication called ML-004 for autism spectrum disorders. It follows 120 adolescents and adults who completed a previous ML-004 study, monitoring them for side effects over time. The main goal is to understand how safe t…
Phase: PHASE2 • Sponsor: MapLight Therapeutics • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
New autism medication trial aims to ease social challenges
Symptom relief OngoingThis study is testing whether an investigational medication called ML-004 can help improve social communication difficulties in adolescents and adults with autism spectrum disorder (ASD). Approximately 150 participants will be randomly assigned to receive either ML-004 or a place…
Phase: PHASE2 • Sponsor: MapLight Therapeutics • Aim: Symptom relief
Last updated Apr 04, 2026 05:06 UTC